HELICOBACTER

Scope & Guideline

Exploring the Frontiers of Gastroenterology and Infection

Introduction

Delve into the academic richness of HELICOBACTER with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN1083-4389
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1996 to 2024
AbbreviationHELICOBACTER / Helicobacter
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal 'HELICOBACTER' primarily focuses on research related to the bacterium *Helicobacter pylori*, its associated infections, treatment methodologies, and the implications of these infections on gastric health. It aims to disseminate high-quality research that contributes to the understanding and management of *H. pylori* infections.
  1. Clinical Management of *Helicobacter pylori*:
    Research on various treatment regimens, including empirical and tailored therapies, as well as the effectiveness of novel medications like vonoprazan and bismuth-containing therapies.
  2. Antibiotic Resistance Studies:
    Investigation into the resistance patterns of *H. pylori* to various antibiotics, including studies on the genetic and phenotypic resistance mechanisms.
  3. Gastric Cancer and Related Complications:
    Exploration of the relationship between *H. pylori* infection and gastric cancer, including studies on screening, prevention, and the impact of eradication therapies on cancer risk.
  4. Microbiota Interaction and Metabolism:
    Research on how *H. pylori* interacts with the gastric microbiota and its effects on metabolic processes and gastrointestinal health.
  5. Immunological Responses and Vaccine Development:
    Focus on the immune response elicited by *H. pylori* and the development of potential vaccines and immunotherapies.
  6. Epidemiological Studies:
    Surveys and studies analyzing the prevalence of *H. pylori* infection across different populations, age groups, and geographical regions.
The journal has seen a shift towards certain trending and emerging themes that reflect the latest advancements and interests in the field of *H. pylori* research.
  1. Novel Therapeutics and Treatment Strategies:
    A growing focus on innovative treatment strategies, including the use of dual therapy with new drugs like vonoprazan and the evaluation of non-antibiotic options.
  2. Personalized Medicine Approaches:
    Emerging research on tailoring treatment plans based on individual patient factors, such as genetic makeup and antibiotic susceptibility, indicating a shift towards personalized medicine.
  3. Impact of Microbiota on Treatment Outcomes:
    Increased attention on how the gut microbiome influences treatment efficacy and patient outcomes, reflecting a growing understanding of microbial interactions.
  4. Global Antibiotic Resistance Trends:
    An expanding body of work dedicated to tracking antibiotic resistance patterns globally, particularly in pediatric and elderly populations, highlights the public health implications of *H. pylori* infections.
  5. Integration of Artificial Intelligence in Treatment:
    The introduction of AI technologies in predicting treatment outcomes and enhancing patient education materials indicates a trend towards leveraging technology in clinical settings.
  6. Long-Term Effects of Eradication Therapy:
    Research examining the long-term outcomes and potential complications following *H. pylori* eradication therapy, including its impact on gastric health and cancer risk.

Declining or Waning

While the journal continues to publish a wide range of topics, certain areas of research seem to be declining in frequency or prominence in recent publications.
  1. Basic Microbiological Studies:
    There has been a noticeable decrease in fundamental research focusing solely on the microbiological characteristics of *H. pylori*, such as its metabolism and basic physiology, as the focus shifts to clinical and therapeutic applications.
  2. Single-Agent Therapy Studies:
    Research centered on single-agent therapies for *H. pylori* eradication is becoming less common, as combination therapies and novel regimens are now preferred.
  3. Older Eradication Regimens:
    There is a waning interest in older treatment regimens and their comparative effectiveness, with current research emphasizing newer therapies and their long-term outcomes.
  4. Animal Model Studies:
    The use of animal models for *H. pylori* research appears to be decreasing, potentially as clinical studies gain more relevance and priority.
  5. Non-Gastrointestinal Implications:
    Studies exploring the implications of *H. pylori* infection beyond the gastrointestinal tract, such as its potential links to systemic diseases, are being published less frequently.

Similar Journals

JOURNAL OF MICROBIOLOGY

Empowering researchers to shape the future of microbiology.
Publisher: MICROBIOLOGICAL SOCIETY KOREAISSN: 1225-8873Frequency: 12 issues/year

JOURNAL OF MICROBIOLOGY, published by the Microbiological Society Korea, is a prestigious peer-reviewed journal dedicated to the advancement of knowledge in the fields of microbiology, applied microbiology, and biotechnology. Established in 1996, this journal serves as a vital platform for researchers and professionals from around the globe to disseminate their findings and engage in multidisciplinary discussions pertaining to microbial sciences. With an H-index that reflects its impact, the journal holds a commendable Q2 ranking in key categories including Applied Microbiology and Biotechnology, as well as Medicine (Miscellaneous), which underscores its significance in the academic community. Despite being a subscription-based journal, the JOURNAL OF MICROBIOLOGY aims to contribute to the understanding of microbial processes and their applications, facilitating advancements that are essential in health, industry, and environmental sciences. Researchers, students, and practitioners are encouraged to explore this rich resource for the latest research and trends in microbiology.

Infectious Diseases and Therapy

Advancing global health through groundbreaking research.
Publisher: SPRINGER LONDON LTDISSN: 2193-8229Frequency: 4 issues/year

Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.

BIOORGANIC CHEMISTRY

Advancing the frontiers of biochemistry and organic chemistry.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCEISSN: 0045-2068Frequency: 12 issues/year

BIOORGANIC CHEMISTRY, published by Academic Press Inc., a prestigious imprint of Elsevier Science, represents a cornerstone in the fields of biochemistry, organic chemistry, and drug discovery. With an impressive Scopus rank placing it in the top quartiles across critical categories—including Q2 for Biochemistry and Drug Discovery, and Q1 for Organic Chemistry—this journal has established itself as a vital resource for researchers, professionals, and students alike. Featuring a diverse array of articles that explore innovative methodologies and emerging trends from 1971 to the present, BIOORGANIC CHEMISTRY effectively bridges the gap between laboratory research and practical applications. Although not an Open Access journal, its rigorous peer-review process ensures the delivery of high-quality, impactful research that drives advances in the understanding and application of biochemistry. With an aim to facilitate scientific discourse and collaboration, it invites contributions that further the exploration of chemical processes within biological systems.

ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA

Shaping the future of microbiological inquiry.
Publisher: AKADEMIAI KIADO ZRTISSN: 1217-8950Frequency: 4 issues/year

ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA is a distinguished academic journal published by AKADEMIAI KIADO ZRT, focusing on significant advancements in the fields of microbiology, immunology, and infectious diseases. Established in 1994, this journal serves as a vital platform for researchers, professionals, and students keen on exploring the complexities of microbial interactions and immune responses. With a current Impact Factor reflecting its rank within the Q3 categories for Immunology, Microbiology, and Infectious Diseases, it retains a critical position in disseminating innovative research. Although not open access, the journal provides extensive insights disseminated through various academic databases, ensuring a broad reach within the scholarly community. Its convergence over three decades indicates a robust commitment to excellence in scientific inquiry and knowledge sharing. As it moves towards the future, ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA continues to uphold its legacy of fostering collaborative research initiatives that contribute to the understanding and treatment of microbial diseases globally.

DRUG RESISTANCE UPDATES

Pioneering insights in cancer and infectious disease management.
Publisher: CHURCHILL LIVINGSTONEISSN: 1368-7646Frequency: 6 issues/year

DRUG RESISTANCE UPDATES is a premier academic journal published by Churchill Livingstone, focusing on the critical areas of drug resistance in various diseases including cancer, infectious diseases, and the pharmacological challenges associated with these conditions. With a robust impact factor and a prestigious Q1 ranking across multiple categories such as Cancer Research, Infectious Diseases, and Pharmacology, this journal is recognized for its significant contributions to the field. Since its inception in 1998 and continuing through to 2024, it has become an essential resource for researchers, clinicians, and policy-makers aiming to understand and combat the evolving challenges of drug resistance. Although it is not an open-access publication, it provides vital insights and research findings that are pivotal in influencing treatment strategies and advancing knowledge within the scientific community. For stellar insights backed by rigorous peer review, DRUG RESISTANCE UPDATES should be on the radar of every professional concerned with the intricacies of modern medicine and pharmacology.

CHEMOTHERAPY

Innovating Therapeutic Strategies for Tomorrow's Medicine
Publisher: KARGERISSN: 0009-3157Frequency: 4 issues/year

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Innovating solutions for infectious disease challenges.
Publisher: ELSEVIER SCI LTDISSN: 1201-9712Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, published by ELSEVIER SCI LTD, stands as a leading platform in the realm of infectious diseases, contributing significantly to the global understanding of this critical field. With an impressive impact factor, the journal maintains a distinguished Q1 ranking across various categories, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, demonstrating its high relevance and influence among contemporary research. Since its inception in 1996, it has embraced an Open Access model, allowing for wider dissemination of essential research findings that can inform public health policies and clinical practices. With a commitment to advancing scientific knowledge, this journal is not only a vital resource for researchers and professionals but also serves as an invaluable educational tool for students interested in the complexities of infectious diseases and their management. For those looking to stay at the forefront of research and innovation in this field, the INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES is an indispensable resource.

World Journal of Gastrointestinal Oncology

Bridging the gap between research and clinical application in gastrointestinal health.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1948-5204Frequency: 12 issues/year

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

Microbial Drug Resistance

Advancing the Fight Against Antibiotic Resistance
Publisher: MARY ANN LIEBERT, INCISSN: 1076-6294Frequency: 10 issues/year

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases

Elevating Standards in Tuberculosis Management
Publisher: ELSEVIERISSN: 2405-5794Frequency: 4 issues/year

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases is a leading peer-reviewed journal dedicated to advancing the field of infectious diseases, particularly focusing on tuberculosis and other mycobacterial infections. Published by ELSEVIER in the United Kingdom with an impressive open access model since 2015, this journal aims to provide a platform for the dissemination of high-quality research, clinical findings, and innovative methodologies in the management of mycobacterial diseases. With a commendable impact, the journal currently holds a Q2 ranking in multiple categories including Infectious Diseases and Pulmonary and Respiratory Medicine, reflecting its influence in the academic community. The journal is dedicated to serving researchers, healthcare professionals, and students by offering access to essential information that can improve patient outcomes and enhance public health strategies. As the field of mycobacterial diseases continues to evolve, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases remains a crucial resource for those seeking to remain at the forefront of research and clinical practice.